- Home
- CRBP vs EDF Comparison
CRBP vs EDF Comparison
Compare CRBP & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- EDF
- Stock Information
- Founded
- CRBP 2009
- EDF 2010
- Country
- CRBP United States
- EDF United States
- Employees
- CRBP 19
- EDF N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- EDF Investment Managers
- Sector
- CRBP Health Care
- EDF Finance
- Exchange
- CRBP Nasdaq
- EDF Nasdaq
- Market Cap
- CRBP 158.3M
- EDF 148.6M
- IPO Year
- CRBP N/A
- EDF N/A
- Fundamental
- Price
- CRBP $13.00
- EDF $4.74
- Analyst Decision
- CRBP Strong Buy
- EDF
- Analyst Count
- CRBP 8
- EDF 0
- Target Price
- CRBP $62.00
- EDF N/A
- AVG Volume (30 Days)
- CRBP 313.3K
- EDF 160.6K
- Earning Date
- CRBP 11-07-2024
- EDF 01-01-0001
- Dividend Yield
- CRBP N/A
- EDF 13.14%
- EPS Growth
- CRBP N/A
- EDF N/A
- EPS
- CRBP N/A
- EDF N/A
- Revenue
- CRBP N/A
- EDF N/A
- Revenue This Year
- CRBP N/A
- EDF N/A
- Revenue Next Year
- CRBP N/A
- EDF N/A
- P/E Ratio
- CRBP N/A
- EDF N/A
- Revenue Growth
- CRBP N/A
- EDF N/A
- 52 Week Low
- CRBP $5.25
- EDF $3.51
- 52 Week High
- CRBP $61.90
- EDF $5.50
- Technical
- Relative Strength Index (RSI)
- CRBP 25.10
- EDF 37.88
- Support Level
- CRBP $12.90
- EDF $4.90
- Resistance Level
- CRBP $16.21
- EDF $5.14
- Average True Range (ATR)
- CRBP 0.95
- EDF 0.09
- MACD
- CRBP -0.16
- EDF -0.04
- Stochastic Oscillator
- CRBP 1.69
- EDF 25.94
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund invests predominantly invests in fixed income securities and other instruments economically tied to emerging market countries.